Stoke Therapeutics, Inc. STOK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $155.66M+84.8% | $84.22M+1.0% | $83.39M-17.8% | $101.47M-63.1% | $274.82M+115% | ||
| $187.89M-6.3% | $200.45M+21.5% | $164.92M+12.8% | $146.24M+77.2% | $82.51M— | ||
| $3.23M+553% | $494K— | $0-100% | $75K0.0% | $75K0.0% | ||
| —— | —— | —— | —— | $3.02M+77.0% | ||
| $10.12M+15.8% | $8.74M+12.8% | $7.75M-43.4% | $13.69M+7.9% | $12.69M+14.2% | ||
| $1.69M-14.2% | $1.97M+23.9% | $1.59M-2.0% | $1.62M+168% | $606K-13.4% | ||
| $366.68M+19.9% | $305.7M+12.2% | $272.44M+0.9% | $269.97M-28.1% | $375.74M+61.4% | ||
| $3.4M+7.9% | $3.15M+2.0% | $3.08M-7.8% | $3.34M-7.4% | $3.61M-7.6% | ||
| $2.49M-19.6% | $3.1M+72.3% | $1.8M-44.1% | $3.22M-16.0% | $3.83M-11.8% | ||
| $67.48M-36.5% | $106.26M+32.3% | $80.32M-25.1% | $107.26M— | —— | ||
| $443.28M+5.9% | $418.43M+16.1% | $360.26M-6.3% | $384.51M-5.5% | $406.89M+49.8% | ||
| $6.84M+38.5% | $4.94M-15.9% | $5.87M+36.1% | $4.31M+97.3% | $2.19M-12.5% | ||
| $6.6M-5.1% | $6.96M— | —— | —— | —— | ||
| $2.43M-19.1% | $3.01M+3.4% | $2.91M+26.7% | $2.3M-2.3% | $2.35M+1.2% | ||
| $40.81M-29.5% | $57.88M+38.7% | $41.73M+7.9% | $38.68M-13.4% | $44.69M+11.6% | ||
| $3.42M-17.5% | $4.15M+130% | $1.8M-65.9% | $5.28M-11.2% | $5.95M+24.6% | ||
| $991K-13.1% | $1.14M-39.1% | $1.87M+49.3% | $1.26M-33.0% | $1.87M-24.4% | ||
| $7.59M-6.3% | $8.1M-22.3% | $10.43M-4.2% | $10.89M-10.2% | $12.13M+389% | ||
| $48.4M-26.6% | $65.98M+26.5% | $52.16M+5.2% | $49.57M-12.8% | $56.81M+33.6% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $942.7M+11.0% | $849.62M+13.7% | $747.44M+1.5% | $736.28M+1.1% | $728.12M+1.1% | ||
| -$547.72M-10.0% | -$497.72M-13.2% | -$439.78M-9.6% | -$401.43M-6.2% | -$377.95M+23.0% | ||
| -$115K-121% | $543K+21.7% | $446K+365% | $96K+192% | -$104K— | ||
| $394.88M+12.0% | $352.46M+14.4% | $308.11M-8.0% | $334.94M-4.3% | $350.07M+52.9% | ||
| $443.28M+5.9% | $418.43M+16.1% | $360.26M-6.3% | $384.51M-5.5% | $406.89M+49.8% | ||
| $187.89M-6.3% | $200.45M+21.5% | $164.92M+12.8% | $146.24M+77.2% | $82.51M— | ||
| $6.88M+56.8% | $4.39M-20.8% | $5.54M-19.3% | $6.87M+36.4% | $5.04M+119% | ||
| $2.49M-19.6% | $3.1M+72.3% | $1.8M-44.1% | $3.22M-16.0% | $3.83M-11.8% | ||
| $67.48M-36.5% | $106.26M+32.3% | $80.32M-25.1% | $107.26M— | —— | ||
| $2.49M-19.6% | $3.1M+72.3% | $1.8M-44.1% | $3.22M-16.0% | $3.83M-11.8% | ||
| $2.49M-19.6% | $3.1M+72.3% | $1.8M-44.1% | $3.22M-16.0% | $3.83M-11.8% | ||
| $23.9M-41.8% | $41.04M+36.4% | $30.09M+17.5% | $25.62M+5.3% | $24.34M+31.1% | ||
| $10.07M-15.4% | $11.9M+107% | $5.76M-34.1% | $8.75M-51.8% | $18.16M-4.4% | ||
| $6.6M-5.1% | $6.96M— | —— | —— | —— | ||
| $3.42M-17.5% | $4.15M+130% | $1.8M-65.9% | $5.28M-11.2% | $5.95M+24.6% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $1.69M-14.2% | $1.97M+23.9% | $1.59M-2.0% | $1.62M+168% | $606K-13.4% | ||
| $10.12M+15.8% | $8.74M+12.8% | $7.75M-43.4% | $13.69M+7.9% | $12.69M+14.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Stoke Therapeutics, Inc.'s total assets?
- Stoke Therapeutics, Inc. (STOK) holds $443.3M in total assets, up 8.9% year over year.
- How much debt does Stoke Therapeutics, Inc. have?
- Stoke Therapeutics, Inc. carries $3.4M in total debt against $394.9M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Stoke Therapeutics, Inc. have?
- Stoke Therapeutics, Inc. holds $155.7M in cash and equivalents.
- Can Stoke Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.99 — current assets exceed current liabilities.
- Where does Stoke Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
